PDGF receptor signaling networks in normal and cancer cells

Cytokine and Growth Factor Reviews

Volumn 25, Issue 3, 2014, Pages 273-283

  Demoulin, Jean Baptiste ^a   Essaghir, Ahmed ^a  

^a DE DUVE INSTITUTE   (Belgium)

Author keywords

Myeloproliferative neoplasms; Oncogenes; PDGFRA; PDGFRB; Receptor tyrosine kinase

Indexed keywords

CALCIUM; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; STAT1 PROTEIN; STAT3 PROTEIN; VASCULOTROPIN A; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

APOPTOSIS; BINDING AFFINITY; CANCER CELL; CELL PROLIFERATION; DERMATOFIBROSARCOMA PROTUBERANS; ENDOCYTOSIS; EXON; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; LEUKEMIA; LIGAND BINDING; MYELOID LEUKEMIA; NONHUMAN; ONCOGENE; PDGF B GENE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; FIBROSIS; GASTROINTESTINAL STROMAL TUMORS; HYPEREOSINOPHILIC SYNDROME; INFECTION; METABOLISM; PATHOLOGY; STROKE;

BENZAMIDES; FIBROSIS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; HYPEREOSINOPHILIC SYNDROME; INFECTION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION; STROKE;

EID: 84902087291     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.03.003     Document Type: Review

References (160)

1. Ross R., Glomset J., Kariya B., Harker L. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci U S A 1974, 71:1207-1210.
2. Westermark B., Wasteson A. A platelet factor stimulating human normal glial cells. Exp Cell Res 1976, 98:170-174.
3. Kohler N., Lipton A. Platelets as a source of fibroblast growth-promoting activity. Exp Cell Res 1974, 87:297-301.
4. Waterfield M.D., Scrace G.T., Whittle N., Stroobant P., Johnsson A., Wasteson A., et al. Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus. Nature 1983, 304:35-39.
5. Yarden Y., Escobedo J.A., Kuang W.J., Yang-Feng T.L., Daniel T.O., Tremble P.M., et al. Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature 1986, 323:226-232.
6. Ek B., Westermark B., Wasteson A., Heldin C.H. Stimulation of tyrosine-specific phosphorylation by platelet-derived growth factor. Nature 1982, 295:419-420.
7. Ostman A., Heldin C.H. PDGF receptors as targets in tumor treatment. Adv Cancer Res 2007, 97:247-274.
8. Andrae J., Gallini R., Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008, 22:1276-1312.
9. Fredriksson L., Li H., Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 2004, 15:197-204.
10. Lindblom P., Gerhardt H., Liebner S., Abramsson A., Enge M., Hellstrom M., et al. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev 2003, 17:1835-1840.
11. Bergsten E., Uutela M., Li X., Pietras K., Östman A., Heldin C.H., et al. PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol 2001, 3:512-516.
12. Li X., Ponten A., Aase K., Karlsson L., Abramsson A., Uutela M., et al. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol 2000, 2:302-309.
13. Fredriksson L., Li H., Fieber C., Li X., Eriksson U. Tissue plasminogen activator is a potent activator of PDGF-CC. Embo J 2004, 23:3793-3802.
14. Su E.J., Fredriksson L., Geyer M., Folestad E., Cale J., Andrae J., et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 2008, 14:731-737.
15. Heeneman S., Haendeler J., Saito Y., Ishida M., Berk B.C. Angiotensin II induces transactivation of two different populations of the platelet-derived growth factor beta receptor. Key role for the p66 adaptor protein Shc. J Biol Chem 2000, 275:15926-15932.
16. Gill R.S., Hsiung M.S., Sum C.S., Lavine N., Clark S.D., Van Tol H.H. The dopamine D4 receptor activates intracellular platelet-derived growth factor receptor beta to stimulate ERK1/2. Cell Signal 2010, 22:285-290.
17. Siegbahn A., Johnell M., Nordin A., Aberg M., Velling T. TF/FVIIa transactivate PDGFRbeta to regulate PDGF-BB-induced chemotaxis in different cell types: involvement of Src and PLC. Arterioscler Thromb Vasc Biol 2008, 28:135-141.
18. Gao B.B., Hansen H., Chen H.C., Feener E.P. Angiotensin II stimulates phosphorylation of an ectodomain-truncated platelet-derived growth factor receptor-beta and its binding to class IA PI3K in vascular smooth muscle cells. Biochem J 2006, 397:337-344.
19. Ball S.G., Shuttleworth C.A., Kielty C.M. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol 2007, 177:489-500.
20. Pennock S., Kazlauskas A. Vascular endothelial growth factor A competitively inhibits platelet-derived growth factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses. Mol Cell Biol 2012, 32:1955-1966.
21. Lindahl P., Johansson B.R., Leveen P., Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997, 277:242-245.
22. Soriano P. The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. Development 1997, 124:2691-2700.
23. Ding H., Wu X., Bostrom H., Kim I., Wong N., Tsoi B., et al. A specific requirement for PDGF-C in palate formation and PDGFR-alpha signaling. Nat Genet 2004, 36:1111-1116.
24. Klinghoffer R.A., Mueting-Nelsen P.F., Faerman A., Shani M., Soriano P. The two PDGF receptors maintain conserved signaling in vivo despite divergent embryological functions. Mol Cell 2001, 7:343-354.
25. Papanas N., Maltezos E. Becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Clin Interv Aging 2008, 3:233-240.
26. Buetow B.S., Crosby J.R., Kaminski W.E., Ramachandran R.K., Lindahl P., Martin P., et al. Platelet-derived growth factor B-chain of hematopoietic origin is not necessary for granulation tissue formation and its absence enhances vascularization. Am J Pathol 2001, 159:1869-1876.
27. Heuchel R., Berg A., Tallquist M., Ahlen K., Reed R.K., Rubin K., et al. Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3' kinase signaling. Proc Natl Acad Sci U S A 1999, 96:11410-11415.
28. Toffalini F., Demoulin J.B. New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases. Blood 2010, 116:2429-2437.
29. Heldin C.H. Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal 2013, 11:97.
30. Velghe A.I., Van Cauwenberghe S., Polyansky A.A., Chand D., Montano-Almendras C.P., Charni S., et al. PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations. Oncogene 2014, 10.1038/onc.2013.218.
31. Medves S., Demoulin J.B. Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies. J Cell Mol Med 2012, 16:237-248.
32. Demoulin J.B., Montano-Almendras C.P. Platelet-derived growth factors and their receptors in normal and malignant hematopoiesis. Am J Blood Res 2012, 2:44-56.
33. Havelange V., Demoulin J.B. Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia. J Blood Med 2013, 4:111-121.
34. Baroni S.S., Santillo M., Bevilacqua F., Luchetti M., Spadoni T., Mancini M., et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006, 354:2667-2676.
35. Classen J.F., Henrohn D., Rorsman F., Lennartsson J., Lauwerys B.R., Wikstrom G., et al. Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum 2009, 60:1137-1144.
36. Demoulin J.B., Kampe O., Rorsman F., Scleroderma N Engl J Med 2009, 361:826.
37. Loizos N., Lariccia L., Weiner J., Griffith H., Boin F., Hummers L., et al. Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera. Arthritis Rheum 2009, 60:1145-1151.
38. Chen G.L., Arai S., Flowers M.E., Otani J.M., Qiu J., Cheng E.C., et al. A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Blood 2011, 118:4070-4078.
39. Borzacchiello G., Russo V., Gentile F., Roperto F., Venuti A., Nitsch L., et al. Bovine papillomavirus E5 oncoprotein binds to the activated form of the platelet-derived growth factor beta receptor in naturally occurring bovine urinary bladder tumours. Oncogene 2006, 25:1251-1260.
40. Soroceanu L., Akhavan A., Cobbs C.S. Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Nature 2008, 455:391-395.
41. Vanarsdall A.L., Wisner T.W., Lei H., Kazlauskas A., Johnson D.C. PDGF receptor-alpha does not promote HCMV entry into epithelial and endothelial cells but increased quantities stimulate entry by an abnormal pathway. PLoS Pathog 2012, 8:e1002905.
42. Di Pasquale G., Davidson B.L., Stein C.S., Martins I., Scudiero D., Monks A., et al. Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 2003, 9:1306-1312.
43. Pilz I.H., Di Pasquale G., Rzadzinska A., Leppla S.H., Chiorini J.A. Mutation in the platelet-derived growth factor receptor alpha inhibits adeno-associated virus type 5 transduction. Virology 2012, 428:58-63.
44. Elwell C.A., Ceesay A., Kim J.H., Kalman D., Engel J.N. RNA interference screen identifies Abl kinase and PDGFR signaling in Chlamydia trachomatis entry. PLoS Pathog 2008, 4:e1000021.
45. Pardanani A., D'Souza A., Knudson R.A., Hanson C.A., Ketterling R.P., Tefferi A. Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome. Leukemia 2012, 26:2439-2441.
46. Lierman E., Michaux L., Beullens E., Pierre P., Marynen P., Cools J., et al. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia 2009, 23:845-851.
47. Reardon D.A., Dresemann G., Taillibert S., Campone M., van den Bent M., Clement P., et al. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer 2009, 101:1995-2004.
48. Heldin C.H. Targeting the PDGF signaling pathway in the treatment of non-malignant diseases. J Neuroimmun Pharmacol 2014, 9:69-79.
49. Omura T., Heldin C.H., Ostman A. Immunoglobulin-like domain 4-mediated receptor-receptor interactions contribute to platelet-derived growth factor-induced receptor dimerization. J Biol Chem 1997, 272:12676-12682.
50. Chiara F., Bishayee S., Heldin C.H., Demoulin J.B. Autoinhibition of the platelet-derived growth factor beta-receptor tyrosine kinase by its C-terminal tail. J Biol Chem 2004, 279:19732-19738.
51. Wardega P., Heldin C.H., Lennartsson J. Mutation of tyrosine residue 857 in the PDGF beta-receptor affects cell proliferation but not migration. Cell Signal 2010, 22:1363-1368.
52. DeMali K.A., Kazlauskas A. Activation of Src family members is not required for the platelet-derived growth factor beta receptor to initiate mitogenesis. Mol Cell Biol 1998, 18:2014-2022.
53. Klinghoffer R.A., Sachsenmaier C., Cooper J.A., Soriano P. Src family kinases are required for integrin but not PDGFR signal transduction. EMBO J 1999, 18:2459-2471.
54. Broome M.A., Courtneidge S.A. No requirement for src family kinases for PDGF signaling in fibroblasts expressing SV40 large T antigen. Oncogene 2000, 19:2867-2869.
55. Cain J.A., Xiang Z., O'Neal J., Kreisel F., Colson A., Luo H., et al. Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage. Blood 2007, 109:3906-3914.
56. Blake R.A., Broome M.A., Liu X., Wu J., Gishizky M., Sun L., et al. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol 2000, 20:9018-9027.
57. Hansen K., Johnell M., Siegbahn A., Rorsman C., Engstrom U., Wernstedt C., et al. Mutation of a Src phosphorylation site in the PDGF beta-receptor leads to increased PDGF-stimulated chemotaxis but decreased mitogenesis. EMBO J 1996, 15:5299-5313.
58. Amanchy R., Zhong J., Hong R., Kim J.H., Gucek M., Cole R.N., et al. Identification of c-Src tyrosine kinase substrates in platelet-derived growth factor receptor signaling. Mol Oncol 2009, 3:439-450.
59. Plattner R., Kadlec L., DeMali K.A., Kazlauskas A., Pendergast A.M. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev 1999, 13:2400-2411.
60. Plattner R., Koleske A.J., Kazlauskas A., Pendergast A.M. Bidirectional signaling links the Abelson kinases to the platelet-derived growth factor receptor. Mol Cell Biol 2004, 24:2573-2583.
61. Furstoss O., Dorey K., Simon V., Barila D., Superti-Furga G., Roche S. c-Abl is an effector of Src for growth factor-induced c-myc expression and DNA synthesis. EMBO J 2002, 21:514-524.
62. Plattner R., Irvin B.J., Guo S., Blackburn K., Kazlauskas A., Abraham R.T., et al. A new link between the c-Abl tyrosine kinase and phosphoinositide signalling through PLC-gamma1. Nat Cell Biol 2003, 5:309-319.
63. Boureux A., Furstoss O., Simon V., Roche S. Abl tyrosine kinase regulates a Rac/JNK and a Rac/Nox pathway for DNA synthesis and Myc expression induced by growth factors. J Cell Sci 2005, 118:3717-3726.
64. Chiariello M., Marinissen M.J., Gutkind J.S. Regulation of c-myc expression by PDGF through Rho GTPases. Nat Cell Biol 2001, 3:580-586.
65. Feng H., Hu B., Liu K.W., Li Y., Lu X., Cheng T., et al. Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFRalpha-stimulated glioma tumorigenesis in mice and humans. J Clin Invest 2011, 121:4670-4684.
66. Bowman T., Broome M.A., Sinibaldi D., Wharton W., Pledger W.J., Sedivy J.M., et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A 2001, 98:7319-7324.
67. Craig A.W., Zirngibl R., Williams K., Cole L.A., Greer P.A. Mice devoid of fer protein-tyrosine kinase activity are viable and fertile but display reduced cortactin phosphorylation. Mol Cell Biol 2001, 21:603-613.
68. Lennartsson J., Ma H., Wardega P., Pelka K., Engstrom U., Hellberg C., et al. The Fer tyrosine kinase is important for platelet-derived growth factor-BB-induced signal transducer and activator of transcription 3 (STAT3) protein phosphorylation, colony formation in soft agar, and tumor growth in vivo. J Biol Chem 2013, 288:15736-15744.
69. Hanada M., Feng J., Hemmings B.A. Structure, regulation and function of PKB/AKT - a major therapeutic target. Biochim Biophys Acta 2004, 1697:3-16.
70. Heldin C.H., Östman A., Rönnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta 1998, 1378:F79-F113.
71. Essaghir A., Dif N., Marbehant C.Y., Coffer P.J., Demoulin J.B. The transcription of FOXO genes is stimulated by FOXO3 and repressed by growth factors. J Biol Chem 2009, 284:10334-10342.
72. Adachi M., Osawa Y., Uchinami H., Kitamura T., Accili D., Brenner D.A. The forkhead transcription factor FoxO1 regulates proliferation and transdifferentiation of hepatic stellate cells. Gastroenterology 2007, 132:1434-1446.
73. Abid M.R., Yano K., Guo S., Patel V.I., Shrikhande G., Spokes K.C., et al. Forkhead transcription factors inhibit vascular smooth muscle cell proliferation and neointimal hyperplasia. J Biol Chem 2005, 280:29864-29873.
74. Romashkova J.A., Makarov S.S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999, 401:86-90.
75. Rauch B.H., Weber A., Braun M., Zimmermann N., Schror K. PDGF-induced Akt phosphorylation does not activate NF-kappa B in human vascular smooth muscle cells and fibroblasts. FEBS Lett 2000, 481:3-7.
76. Peppel K., Zhang L., Orman E.S., Hagen P.O., Amalfitano A., Brian L., et al. Activation of vascular smooth muscle cells by TNF and PDGF: overlapping and complementary signal transduction mechanisms. Cardiovasc Res 2005, 65:674-682.
77. Montano-Almendras C.P., Essaghir A., Schoemans H., Varis I., Noel L.A., Velghe A.I., et al. ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor proliferation and differentiation into eosinophils: role of NF-kappaB. Haematologica 2012, 97:1064-1072.
78. Shimamura T., Hsu T.C., Colburn N.H., Bejcek B.E. Activation of NF-kappaB is required for PDGF-B chain to transform NIH3T3 cells. Exp Cell Res 2002, 274:157-167.
79. Besancon F., Atfi A., Gespach C., Cayre Y.E., Bourgeade M.F. Evidence for a role of NF-kappaB in the survival of hematopoietic cells mediated by interleukin 3 and the oncogenic TEL/platelet-derived growth factor receptor beta fusion protein. Proc Natl Acad Sci U S A 1998, 95:8081-8086.
80. Demoulin J.B., Ericsson J., Kallin A., Rorsman C., Ronnstrand L., Heldin C.H. Platelet-derived growth factor stimulates membrane lipid synthesis through activation of phosphatidylinositol 3-kinase and sterol regulatory element-binding proteins. J Biol Chem 2004, 279:35392-35402.
81. Sundqvist A., Bengoechea-Alonso M.T., Ye X., Lukiyanchuk V., Jin J., Harper J.W., et al. Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab 2005, 1:379-391.
82. Porstmann T., Santos C.R., Griffiths B., Cully M., Wu M., Leevers S., et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab 2008, 8:224-236.
83. Klinghoffer R.A., Hamilton T.G., Hoch R., Soriano P. An allelic series at the PDGFalphaR locus indicates unequal contributions of distinct signaling pathways during development. Dev Cell 2002, 2:103-113.
84. Brachmann S.M., Yballe C.M., Innocenti M., Deane J.A., Fruman D.A., Thomas S.M., et al. Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement. Mol Cell Biol 2005, 25:2593-2606.
85. Takahashi Y., Morales F.C., Kreimann E.L., Georgescu M.M. PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling. EMBO J 2006, 25:910-920.
86. Maudsley S., Zamah A.M., Rahman N., Blitzer J.T., Luttrell L.M., Lefkowitz R.J., et al. Platelet-derived growth factor receptor association with Na(+)/H(+) exchanger regulatory factor potentiates receptor activity. Mol Cell Biol 2000, 20:8352-8363.
87. +-exchanger regulatory factor to the PDGF (platelet-derived growth factor) receptor regulates actin cytoskeleton reorganization by PDGF. Biochem J 2003, 376:505-510.
88. + exchanger regulatory factor) gene mutations in human breast cancer. Oncogene 2004, 23:8681-8687.
89. Kallin A., Demoulin J.B., Nishida K., Hirano T., Ronnstrand L., Heldin C.H. Gab1 contributes to cytoskeletal reorganization and chemotaxis in response to platelet-derived growth factor. J Biol Chem 2004, 279:17897-17904.
90. Ronnstrand L., Arvidsson A.K., Kallin A., Rorsman C., Hellman U., Engstrom U., et al. SHP-2 binds to Tyr763 and Tyr1009 in the PDGF beta-receptor and mediates PDGF-induced activation of the Ras/MAP kinase pathway and chemotaxis. Oncogene 1999, 18:3696-3702.
91. Shi Z.Q., Lu W., Feng G.S. The Shp-2 tyrosine phosphatase has opposite effects in mediating the activation of extracellular signal-regulated and c-Jun NH2-terminal mitogen-activated protein kinases. J Biol Chem 1998, 273:4904-4908.
92. Bazenet C.E., Gelderloos J.A., Kazlauskas A. Phosphorylation of tyrosine 720 in the platelet-derived growth factor alpha receptor is required for binding of Grb2 and SHP-2 but not for activation of Ras or cell proliferation. Mol Cell Biol 1996, 16:6926-6936.
93. Noël L.A., Arts F.A., Montano-Almendras C.P., Cox L., Gielen O., Toffalini F., et al. The tyrosine phosphatase SHP2 is required for cell transformation by the receptor tyrosine kinase mutants FIP1L1-PDGFRA and PDGFRA D842V. Mol Oncol 2014, 10.1016/j.molonc.2014.02.003.
94. Gupta S., Ramjaun A.R., Haiko P., Wang Y., Warne P.H., Nicke B., et al. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 2007, 129:957-968.
95. Ekman S., Kallin A., Engstrom U., Heldin C.H., Ronnstrand L. SHP-2 is involved in heterodimer specific loss of phosphorylation of Tyr771 in the PDGF beta-receptor. Oncogene 2002, 21:1870-1875.
96. Cacalano N.A., Sanden D., Johnston J.A. Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras. Nat Cell Biol 2001, 3:460-465.
97. Jurek A., Amagasaki K., Gembarska A., Heldin C.H., Lennartsson J. Negative and positive regulation of MAPK phosphatase 3 controls platelet-derived growth factor-induced Erk activation. J Biol Chem 2009, 284:4626-4634.
98. Lennartsson J., Burovic F., Witek B., Jurek A., Heldin C.H. Erk 5 is necessary for sustained PDGF-induced Akt phosphorylation and inhibition of apoptosis. Cell Signal 2010, 22:955-960.
99. Amagasaki K., Kaneto H., Heldin C.H., Lennartsson J. c-Jun N-terminal kinase is necessary for platelet-derived growth factor-mediated chemotaxis in primary fibroblasts. J Biol Chem 2006, 281:22173-22179.
100. Matsumoto T., Yokote K., Tamura K., Takemoto M., Ueno H., Saito Y., et al. Platelet-derived growth factor activates p38 mitogen-activated protein kinase through a Ras-dependent pathway that is important for actin reorganization and cell migration. J Biol Chem 1999, 274:13954-13960.
101. Takenaka M., Matsuno H., Ishisaki A., Nakajima K., Hirade K., Takei M., et al. Platelet-derived growth factor-BB phosphorylates heat shock protein 27 in cardiac myocytes. J Cell Biochem 2004, 91:316-324.
102. Lallemand D., Ham J., Garbay S., Bakiri L., Traincard F., Jeannequin O., et al. Stress-activated protein kinases are negatively regulated by cell density. EMBO J 1998, 17:5615-5626.
103. Zhan Y., Kim S., Izumi Y., Izumiya Y., Nakao T., Miyazaki H., et al. Role of JNK, p38, and ERK in platelet-derived growth factor-induced vascular proliferation, migration, and gene expression. Arterioscler Thromb Vasc Biol 2003, 23:795-801.
104. Buitenhuis M., Verhagen L.P., Cools J., Coffer P.J. Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation. Cancer Res 2007, 67:3759-3766.
105. Atfi A., Prunier C., Mazars A., Defachelles A.S., Cayre Y., Gespach C., et al. The oncogenic TEL/PDGFR beta fusion protein induces cell death through JNK/SAPK pathway. Oncogene 1999, 18:3878-3885.
106. Wheadon H., Welham M.J. The coupling of TEL/PDGFbetaR to distinct functional responses is modulated by the presence of cytokine: involvement of mitogen-activated protein kinases. Blood 2003, 102:1480-1489.
107. Izawa Y., Yoshizumi M., Ishizawa K., Fujita Y., Kondo S., Kagami S., et al. Big mitogen-activated protein kinase 1 (BMK1)/extracellular signal regulated kinase 5 (ERK5) is involved in platelet-derived growth factor (PDGF)-induced vascular smooth muscle cell migration. Hypertens Res 2007, 30:1107-1117.
108. Rovida E., Navari N., Caligiuri A., Dello Sbarba P., Marra F. ERK5 differentially regulates PDGF-induced proliferation and migration of hepatic stellate cells. J Hepatol 2008, 48:107-115.
109. Razmara M., Eger G., Rorsman C., Heldin C.H., Lennartsson J. MKP3 negatively modulates PDGF-induced Akt and Erk5 phosphorylation as well as chemotaxis. Cell Signal 2012, 24:635-640.
110. Tallquist M.D., Klinghoffer R.A., Heuchel R., Mueting-Nelsen P.F., Corrin P.D., Heldin C.H., et al. Retention of PDGFR-beta function in mice in the absence of phosphatidylinositol 3'-kinase and phospholipase Cgamma signaling pathways. Genes Dev 2000, 14:3179-3190.
111. Liao H.J., Ji Q.S., Carpenter G. Phospholipase C-gamma1 is required for the induction of immediate early genes by platelet-derived growth factor. J Biol Chem 2001, 276:8627-8630.
112. Frijhoff J., Dagnell M., Augsten M., Beltrami E., Giorgio M., Ostman A. The mitochondrial reactive oxygen species regulator p66Shc controls PDGF-induced signaling and migration through protein tyrosine phosphatase oxidation. Free Radic Biol Med 2013, 68C:268-277.
113. Conrad M., Sandin A., Förster H., Seiler A., Frijhoff J., Dagnell M., et al. 12/15-lipoxygenase-derived lipid peroxides control receptor tyrosine kinase signaling through oxidation of protein tyrosine phosphatases. Proc Natl Acad Sci U S A 2010, 107:15774-15779.
114. Choi M.H., Lee I.K., Kim G.W., Kim B.U., Han Y.H., Yu D.Y., et al. Regulation of PDGF signalling and vascular remodelling by peroxiredoxin II. Nature 2005, 435:347-353.
115. Dagnell M., Frijhoff J., Pader I., Augsten M., Boivin B., Xu J., et al. Selective activation of oxidized PTP1B by the thioredoxin system modulates PDGF-β receptor tyrosine kinase signaling. Proc Natl Acad Sci U S A 2013, 110:13398-13403.
116. Valgeirsdottir S., Paukku K., Silvennoinen O., Heldin C.H., Claesson-Welsh L. Activation of Stat5 by platelet-derived growth factor (PDGF) is dependent on phosphorylation sites in PDGF beta-receptor juxtamembrane and kinase insert domains. Oncogene 1998, 16:505-515.
117. Paukku K., Valgeirsdottir S., Saharinen P., Bergman M., Heldin C.H., Silvennoinen O. Platelet-derived growth factor (PDGF)-induced activation of signal transducer and activator of transcription (Stat) 5 is mediated by PDGF beta-receptor and is not dependent on c-src, fyn, jak1 or jak2 kinases. Biochem J 2000, 345:759-766.
118. Vignais M.L., Sadowski H.B., Watling D., Rogers N.C., Gilman M. Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins. Mol Cell Biol 1996, 16:1759-1769.
119. Kriebel P., Patel B.K., Nelson S.A., Grusby M.J., LaRochelle W.J. Consequences of Stat6 deletion on Sis/PDGF- and IL-4-induced proliferation and transcriptional activation in murine fibroblasts. Oncogene 1999, 18:7294-7302.
120. Medves S., Noel L.A., Montano-Almendras C.P., Albu R.I., Schoemans H., Constantinescu S.N., et al. Multiple oligomerization domains of KANK1-PDGFRB are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK. Haematologica 2011, 96:1406-1414.
121. Demoulin J.B., Uyttenhove C., Van Roost E., de Lestre B., Donckers D., Van Snick J., et al. A single tyrosine of the interleukin-9 (IL-9) receptor is required for STAT activation, antiapoptotic activity, and growth regulation by IL-9. Mol Cell Biol 1996, 16:4710-4716.
122. Wang Y.Z., Wharton W., Garcia R., Kraker A., Jove R., Pledger W.J. Activation of Stat3 preassembled with platelet-derived growth factor beta receptors requires Src kinase activity. Oncogene 2000, 19:2075-2085.
123. Masamune A., Satoh M., Kikuta K., Suzuki N., Shimosegawa T. Activation of JAK-STAT pathway is required for platelet-derived growth factor-induced proliferation of pancreatic stellate cells. World J Gastroenterol 2005, 11:3385-3391.
124. Neeli I., Liu Z., Dronadula N., Ma Z.A., Rao G.N. An essential role of the Jak-2/STAT-3/cytosolic phospholipase A(2) axis in platelet-derived growth factor BB-induced vascular smooth muscle cell motility. J Biol Chem 2004, 279:46122-46128.
125. Vignais M.L., Gilman M. Distinct mechanisms of activation of Stat1 and Stat3 by platelet-derived growth factor receptor in a cell-free system. Mol Cell Biol 1999, 19:3727-3735.
126. Yellaturu C.R., Rao G.N. Cytosolic phospholipase A2 is an effector of Jak/STAT signaling and is involved in platelet-derived growth factor BB-induced growth in vascular smooth muscle cells. J Biol Chem 2003, 278:9986-9992.
127. Meraz M.A., White J.M., Sheehan K.C., Bach E.A., Rodig S.J., Dighe A.S., et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996, 84:431-442.
128. Demoulin J.B., Van Roost E., Stevens M., Groner B., Renauld J.C. Distinct roles for STAT1, STAT3, and STAT5 in differentiation gene induction and apoptosis inhibition by interleukin-9. J Biol Chem 1999, 274:25855-25861.
129. Essaghir A., Toffalini F., Knoops L., Kallin A., van Helden J., Demoulin J.B. Transcription factor regulation can be accurately predicted from the presence of target gene signatures in microarray gene expression data. Nucleic Acids Res 2010, 38:e120.
130. Messmer-Blust A.F., Balasubramanian S., Gorbacheva V.Y., Jeyaratnam J.A., Vestal D.J. The interferon-gamma-induced murine guanylate-binding protein-2 inhibits rac activation during cell spreading on fibronectin and after platelet-derived growth factor treatment: role for phosphatidylinositol 3-kinase. Mol Biol Cell 2010, 21:2514-2528.
131. Ramana C.V., Grammatikakis N., Chernov M., Nguyen H., Goh K.C., Williams B.R., et al. Regulation of c-myc expression by IFN-gamma through Stat1-dependent and -independent pathways. EMBO J 2000, 19:263-272.
132. Nakayama A., Nakayama M., Turner C.J., Hoing S., Lepore J.J., Adams R.H. Ephrin-B2 controls PDGFRbeta internalization and signaling. Genes Dev 2013, 27:2576-2589.
133. Muratoglu S.C., Mikhailenko I., Newton C., Migliorini M., Strickland D.K. Low density lipoprotein receptor-related protein 1 (LRP1) forms a signaling complex with platelet-derived growth factor receptor-beta in endosomes and regulates activation of the MAPK pathway. J Biol Chem 2010, 285:14308-14317.
134. Lennartsson J., Wardega P., Engstrom U., Hellman U., Heldin C.H. Alix facilitates the interaction between c-Cbl and platelet-derived growth factor beta-receptor and thereby modulates receptor down-regulation. J Biol Chem 2006, 281:39152-39158.
135. Joazeiro C.A., Wing S.S., Huang H., Leverson J.D., Hunter T., Liu Y.C. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 1999, 286:309-312.
136. Wang Y., Pennock S.D., Chen X., Kazlauskas A., Wang Z. Platelet-derived growth factor receptor-mediated signal transduction from endosomes. J Biol Chem 2004, 279:8038-8046.
137. Kawada K., Upadhyay G., Ferandon S., Janarthanan S., Hall M., Vilardaga J.P., et al. Cell migration is regulated by platelet-derived growth factor receptor endocytosis. Mol Cell Biol 2009, 29:4508-4518.
138. Er E.E., Mendoza M.C., Mackey A.M., Rameh L.E., Blenis J. AKT facilitates EGFR trafficking and degradation by phosphorylating and activating PIKfyve. Sci Signal 2013, 6:ra45.
139. Hellberg C., Schmees C., Karlsson S., Ahgren A., Heldin C.H. Activation of protein kinase C alpha is necessary for sorting the PDGF beta-receptor to Rab4a-dependent recycling. Mol Biol Cell 2009, 20:2856-2863.
140. Toffalini F., Kallin A., Vandenberghe P., Pierre P., Michaux L., Cools J., et al. The fusion proteins TEL-PDGFRbeta and FIP1L1-PDGFRalpha escape ubiquitination and degradation. Haematologica 2009, 94:1085-1093.
141. Toffalini F., Hellberg C., Demoulin J.B. Critical role of the platelet-derived growth factor receptor (PDGFR)-beta transmembrane domain in the TEL-PDGFRbeta cytosolic oncoprotein. J Biol Chem 2010, 285:12268-12278.
142. Clarke I.D., Dirks P.B. A human brain tumor-derived PDGFR-alpha deletion mutant is transforming. Oncogene 2003, 22:722-733.
143. Fruman D.A., Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014, 13:140-156.
144. Patel K.U., Szabo S.S., Hernandez V.S., Prieto V.G., Abruzzo L.V., Lazar A.J., et al. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Hum Pathol 2008, 39:184-193.
145. Ugurel S., Mentzel T., Utikal J., Helmbold P., Mohr P., Pfohler C., et al. Neo-adjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase-II DeCOG trial with long-term follow-up. Clin Cancer Res 2013.
146. David M., Cross N.C., Burgstaller S., Chase A., Curtis C., Dang R., et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007, 109:61-64.
147. Metzgeroth G., Walz C., Erben P., Popp H., Schmitt-Graeff A., Haferlach C., et al. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol 2008, 143:707-715.
148. Medves S., Duhoux F.P., Ferrant A., Toffalini F., Ameye G., Libouton J.M., et al. KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia. Leukemia 2010, 24:1052-1055.
149. Hochhaus A., le Coutre P.D., Kantarjian H.M., Baccarani M., Erben P., Reiter A., et al. Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study. J Cancer Res Clin Oncol 2013, 139:1985-1993.
150. Elling C., Erben P., Walz C., Frickenhaus M., Schemionek M., Stehling M., et al. Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood 2011, 117:2935-2943.
151. Mulligan G., Lichter D.I., Di Bacco A., Blakemore S.J., Berger A., Koenig E., et al. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood 2014, 123:632-639.
152. Corless C.L., Schroeder A., Griffith D., Town A., McGreevey L., Harrell P., et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005, 23:5357-5364.
153. Chompret A., Kannengiesser C., Barrois M., Terrier P., Dahan P., Tursz T., et al. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology 2004, 126:318-321.
154. Huss S., Wardelmann E., Goltz D., Binot E., Hartmann W., Merkelbach-Bruse S., et al. Activating PDGFRA mutations in inflammatory fibroid polyps occur in exons 12, 14 and 18 and are associated with tumour localization. Histopathology 2012, 61:59-68.
155. Dai J., Kong Y., Si L., Chi Z., Cui C., Sheng X., et al. Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib. Clin Cancer Res 2013, 19:6935-6942.
156. Paugh B.S., Zhu X., Qu C., Endersby R., Diaz A.K., Zhang J., et al. Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas. Cancer Res 2013, 73:6219-6229.
157. Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
158. Ozawa T., Brennan C.W., Wang L., Squatrito M., Sasayama T., Nakada M., et al. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev 2010, 24:2205-2218.
159. Martignetti J.A., Tian L., Li D., Ramirez M.C., Camacho-Vanegas O., Camacho S.C., et al. Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis. Am J Hum Genet 2013, 92:1001-1007.
160. Cheung Y.H., Gayden T., Campeau P.M., LeDuc C.A., Russo D., Nguyen V.H., et al. A recurrent PDGFRB mutation causes familial infantile myofibromatosis. Am J Hum Genet 2013, 92:996-1000.